Pharmaceutical Industry Today
Global Oral Solid Dosage Pharmaceutical Formulation Sales Market Report 2018
Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well.
North America dominated the global oral solid dosage pharmaceutical formulation market in revenue terms in 2017, and the trend is projected to continue throughout the forecast period.
The global Oral Solid Dosage Pharmaceutical Formulation market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2018-2025.
Request Sample Copy of the Report @ https://www.qyresearch.com/sample-form/form/524115/global-oral-solid-dosage-pharmaceutical-formulation-sales-market
The major players covered in this report
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Gilead
- Merck
- Novartis
- Pfizer
- AbbVie
- Boehringer Ingelheim
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Immediate Release
- Extended Release
- Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
- Hospital Pharmacy
- Retail Pharmacy
- Drug Stores
- Others
Ask for Discount on Research Report@ https://www.qyresearch.com/request-discount/form/524115/global-oral-solid-dosage-pharmaceutical-formulation-sales-market
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!